Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Significant Synergistic Effect of Peroxisome Proliferator–Activated Receptor γ C-2821T and Diabetes on the Risk of Ischemic Stroke

  1. Fang-I Hsieh, PHD1,2,
  2. Wei-Cheng Lo, MSC1,
  3. Huey-Juan Lin, MD, MPH3,
  4. Yi-Chen Hsieh, PHD1,
  5. Li-Ming Lien, MD, PHD4,
  6. Chyi-Huey Bai, PHD1,5,
  7. Hung-Pin Tseng, MD6 and
  8. Hung-Yi Chiou, PHD1,2
  1. 1School of Public Health, Taipei Medical University, Taipei, Taiwan;
  2. 2Dr. Chi-Chin Huang Stroke Research Center, Taipei Medical University, Taipei, Taiwan;
  3. 3Department of Neurology, Chi-Mei Medical Center, Tainan, Taiwan;
  4. 4Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan;
  5. 5Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan;
  6. 6Department of Neurology, Lotung Poh-Ai Hospital, Lotung, Taiwan.
  1. Corresponding author: Hung-Yi Chiou, hychiou{at}tmu.edu.tw.
Diabetes Care 2009 Nov; 32(11): 2033-2035. https://doi.org/10.2337/dc09-0717
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To explore the relationship between the genetic polymorphisms of PPARγ (Pro12Ala, C1431T, and C-2821T) and the risk of ischemic stroke and to investigate whether these genetic polymorphisms of PPARγ would modify the risk of ischemic stroke among patients with hypertension or diabetes.

RESEARCH DESIGN AND METHODS The case-control study was conducted with 537 ischemic stroke patients and 537 control subjects. A structured questionnaire was used to collect information on conventional cardiovascular risk factors and laboratory results. The genetic polymorphisms of PPARγ were determined by PCR–restriction fragment–length polymorphism.

RESULTS A significant interaction was seen between the −2821C allele and diabetes but not between this allele and hypertension. A markedly elevated risk of ischemic stroke (odds ratio 9.7) was found in the subjects with diabetes and the −2821C allele compared with that in those without these two risk factors.

CONCLUSIONS The −2821C allele of PPARγ was a strong predictor of ischemic stroke for diabetic patients.

Peroxisome proliferator–activated receptor γ (PPARγ) is a ligand-dependent transcription factor involved in the regulation of lipid metabolism and inflammation (1–2). It is expressed in endothelium, vascular smooth muscle cells, macrophages, T-lymphocytes, and human atherosclerotic lesions (3–7). Indeed, PPARγ has been reported to play an important role in the progression of atherosclerosis, which is a well-known risk factor of stroke (8).

PPARγ was proved to prevent postischemic inflammation and neuronal damage in animal studies (9). It may serve as potential targets for treating ischemic stroke. Thus, we aimed to explore the relationship between genetic polymorphisms of PPARγ and the risk of ischemic stroke.

RESEARCH DESIGN AND METHODS

A total of 537 ischemic stroke patients aged 30–95 years and confirmed with computed tomography or magnetic resonance imaging were recruited from the Department of Neurology at Chi-Mei Hospital, Lotung Poh-Ai Hospital, Wan-Fang Hospital, and Taipei Medical University Hospital between 2005 and 2007. A total of 1,636 subjects aged 30–95 years from the health examinations at Shin-Kong WHS Memorial Hospital and Wan-Fang Hospital between 2004 and 2007 were recruited as candidates for the control group. Among these candidates, 34 with a stroke history were excluded. A total of 537 control subjects were then randomly selected from 1,602 candidates and frequency matched by age (±2.5 years) and sex with case subjects. This case-control study was approved by the institutional review board for human subjects, and each subject provided written informed consent prior to the study. A structured questionnaire was used to collect information on conventional cardiovascular risk factors and laboratory results. The genetic polymorphisms of PPARγ (C-2821T, Pro12Ala, and C1431T) were determined by PCR–restriction fragment–length polymorphism. Details are described in the online appendix, available at http://care.diabetesjournals.org/cgi/content/full/dc09-0717/DC1. Student t tests, Mann-Whitney U tests, χ2 tests, and logistic regression models were used as appropriate and performed with the SAS statistical software (version 9.1). Synergy index scores were used to evaluate interaction between two risk factors (10). Pairwise linkage disequilibrium between single nucleotide polymorphism markers was evaluated by Haploview (11).

RESULTS

The occurrences of hypertension (75.6%), diabetes (45.9%), and PPARγ C-2821C genotype (12.3%) were more common in case than in control subjects, but the distribution of Pro12Ala and C1431T was similar between the two groups. The percentage of antihypertension drugs in ischemic stroke case subjects (66.7%) was similar to that in control subjects (66.6%). Of the ischemic stroke case subjects with diabetes, 54.1% had pharmacological treatment. The percentage of pharmacological treatment for diabetes in control subjects (41.5%) was less than that in case subjects. All genetic polymorphisms were in Hardy-Weinberg equilibrium. There was a high degree of linkage disequilibrium between Pro12Ala and C-2821T.

After adjusting for BMI, waist circumference, a history of ever smoking, dyslipidemia, hypertension, diabetes, and pharmacological treatment for diabetes, the odds ratio (OR) of PPARγ C-2821C genotype was not significant. Compared with nondiabetic subjects with T-2821T genotype, an increased risk of ischemic stroke was observed in TT genotype carriers with diabetes (OR 4.2; P = 0.07), and the OR drastically increased to 9.7 (P = 0.008) in C allele carriers but not in C allele carriers without diabetes. Thus, there was a significant joint effect of the PPARγ C-2821T polymorphism and diabetes (synergy − index = 2.7) on the risk of ischemic stroke. On the other hand, no interaction between hypertension and the PPARγ C-2821T polymorphism on the risk of ischemic stroke was found (synergy − index = 0.9).

The risk of ischemic stroke was estimated for each combination of hypertension, diabetes, and the PPARγ −2821C allele, using nonhypertension, non-diabetes, and non-2821C allele carriers as the reference group (Table 1). The ORs of ischemic stroke in hypertension alone or diabetes alone were 2.7 and 3.5, respectively. Furthermore, the OR increased to 5.3 in the subjects with diabetes and the PPARγ −2821C allele, which was higher than the risk in association with hypertension or diabetes alone. The greatest OR (11.6) was seen in the subjects with hypertension, diabetes, and the PPARγ −2821C allele. A trend test indicated that the risk of ischemic stroke increased along with the accumulating number of these three risk factors (P < 0.0001).

View this table:
  • View inline
  • View popup
Table 1

Adjusted ORs of ischemic stroke risk by hypertension, diabetes, and PPARγ −2821C allele

CONCLUSIONS

Our study concluded that there was no relationship between PPARγ Pro12Ala genotype and the risk of ischemic stroke. The same result was found by Zafarmand et al. (12), but the opposite conclusion was made by Lee et al. (13). The data of genetic polymorphism of PPARγ C-2821T in diseases were scarce. This novel genetic variant was first identified in the Pima Indian population from Arizona and was reported to associate with metabolic predictors of type 2 diabetes and obesity (14). In the present study, we found a joint effect of the PPARγ −2821C allele and diabetes on the risk of ischemic stroke. Adjusting for traditional cardiovascular risk factors and pharmacological treatment for diabetes, the risk of ischemic stroke in the −2821C allele carriers with diabetes was 9.7 times greater than that of the homozygous T allele carriers without diabetes. Higher transcriptional activity was found in the −2821T allele than in the −2821C allele by using the Dual Luciferase Reporter Assay in 3T3-L1 cells (14). This implied that PPARγ could present a protective effect on ischemic stroke. Wu et al. (9) used a rat model to prove PPARγ to be a critical factor for protection against neuronal apoptosis and cerebral infarction by the mediated 14-3–3ε protein. In addition, PPARγ was reported to be an important regulator of endothelial function in the cerebral circulation, especially under conditions of high fat–induced stress (15).

In the present study, we found that the risk of ischemic stroke in subjects with hypertension, diabetes, and the −2821C allele was 2.6 times higher than that in the subjects with hypertension and diabetes. Therefore, the combination of hypertension, diabetes, and the PPARγ −2821C allele was a strong predictor of ischemic stroke. Further studies in other populations will be very useful in establishing the contribution of this C-2821T polymorphism to ischemic stroke.

In conclusion, there was a strong interaction between the PPARγ −2821C allele and diabetes with regard to risk of ischemic stroke. Thus, the PPARγ −2821C allele was a strong predictor of ischemic stroke for diabetic patients, and PPARγ may serve as a potential target for treating ischemic stroke.

Acknowledgments

This work was supported by grant NSC96-2314-B-038-016-MY3 from the National Science Council of Taiwan; the Topnotch Stroke Research Center, Ministry of Education; and grant DOH-TD-B-111-002 from the Center of Excellence for Clinical Trial and Research in Neurology and Neurosurgery in Wan Fang Hospital.

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received April 15, 2009.
    • Accepted July 27, 2009.
  • Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

  • © 2009 by the American Diabetes Association.

References

  1. ↵
    1. Tonntonoz P,
    2. Hu E,
    3. Spiegelman BM
    : Stimulation of adipogenesis in fibroblasts by PPARg2, a lipid-activated transcription factor. Cell 1994;79:1147–1156
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Tontonoz P,
    2. Hu E,
    3. Graves RA,
    4. Budavari AI,
    5. Spiegelman BM
    : PPARg2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224–1234
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Satoh H,
    2. Tsukamoto K,
    3. Hashimoto Y,
    4. Hashimoto N,
    5. Togo M,
    6. Hara M,
    7. Maekawa H,
    8. Isoo N,
    9. Kimura S,
    10. Watanabe T
    : Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun 1999;254:757–763
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Law RE,
    2. Goetze S,
    3. Xi XP,
    4. Jackson S,
    5. Kawano Y,
    6. Demer L,
    7. Fishbein MC,
    8. Meehan WP,
    9. Hsueh WA
    : Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000;101:1311–1318
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Marx N,
    2. Sukhova G,
    3. Murphy C,
    4. Libby P,
    5. Plutzky J
    : Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor-γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17–23
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Yang XY,
    2. Wang LH,
    3. Chen T,
    4. Hodge DR,
    5. Resau JH,
    6. DaSilva L,
    7. Farrar WL
    : Activation of human T lymphocytes ischemic stroke inhibited by peroxisome proliferator-activated receptor-γ (PPARγ) agonists: PPARγ co-association with transcription factor NFAT. J Biol Chem 2000;275:4541–4544
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ricote M,
    2. Huang J,
    3. Fajas L,
    4. Li A,
    5. Welch J,
    6. Najib J,
    7. Witztum JL,
    8. Auwerx J,
    9. Palinski W,
    10. Glass CK
    : Expression of the peroxisome proliferator-activated receptor-γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998;95:7614–7619
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Chawla A,
    2. Boisvert WA,
    3. Lee CH,
    4. Laffitte BA,
    5. Barak Y,
    6. Joseph SB,
    7. Liao D,
    8. Nagy L,
    9. Edwards PA,
    10. Curtiss LK,
    11. Evans RM,
    12. Tontonoz P
    : A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161–171
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Wu JS,
    2. Cheung WM,
    3. Tsai YS,
    4. Chen YT,
    5. Fong WH,
    6. Tsai HD,
    7. Chen YC,
    8. Liou JY,
    9. Shyue SK,
    10. Chen JJ,
    11. Chen YE,
    12. Maeda N,
    13. Wu KK,
    14. Lin TN
    : Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 2009;119:1124–1134
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Rothman KJ,
    2. Greenland S
    : Concepts of interaction. In Modern Epidemiology. Philadelphia, Lippincott-Raven Publishers, 1998, p. 329–342
  11. ↵
    1. Barrett JC,
    2. Fry B,
    3. Maller J,
    4. Daly MJ
    : Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Zafarmand MH,
    2. van der Schouw YT,
    3. Grobbee DE,
    4. de Leeuw PW,
    5. Bots ML
    : Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc Health Risk Manag 2008;4:427–436
    OpenUrlPubMed
  13. ↵
    1. Lee BC,
    2. Lee HJ,
    3. Chung JH
    : Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci Lett 2006;410:141–145
    OpenUrlCrossRefPubMed
  14. ↵
    1. Muller YL,
    2. Bogardus C,
    3. Beamer BA,
    4. Shuldiner AR,
    5. Baier LJ
    : A functional variant in the peroxisome proliferator–activated receptor γ2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003;52:1864–1871
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Beyer AM,
    2. de Lange WJ,
    3. Halabi CM,
    4. Modrick ML,
    5. Keen HL,
    6. Faraci FM,
    7. Sigmund CD
    : Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res 2008;103:654–661
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes Care: 32 (11)

In this Issue

November 2009, 32(11)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Significant Synergistic Effect of Peroxisome Proliferator–Activated Receptor γ C-2821T and Diabetes on the Risk of Ischemic Stroke
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Significant Synergistic Effect of Peroxisome Proliferator–Activated Receptor γ C-2821T and Diabetes on the Risk of Ischemic Stroke
Fang-I Hsieh, Wei-Cheng Lo, Huey-Juan Lin, Yi-Chen Hsieh, Li-Ming Lien, Chyi-Huey Bai, Hung-Pin Tseng, Hung-Yi Chiou
Diabetes Care Nov 2009, 32 (11) 2033-2035; DOI: 10.2337/dc09-0717

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Significant Synergistic Effect of Peroxisome Proliferator–Activated Receptor γ C-2821T and Diabetes on the Risk of Ischemic Stroke
Fang-I Hsieh, Wei-Cheng Lo, Huey-Juan Lin, Yi-Chen Hsieh, Li-Ming Lien, Chyi-Huey Bai, Hung-Pin Tseng, Hung-Yi Chiou
Diabetes Care Nov 2009, 32 (11) 2033-2035; DOI: 10.2337/dc09-0717
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Important Drop Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study
  • Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study
  • Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
Show more Original Research

Epidemiology/Health Services Research

  • Comparisons of Polyexposure, Polygenic, and Clinical Risk Scores in Risk Prediction of Type 2 Diabetes
  • Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems
  • Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Show more Epidemiology/Health Services Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.